Morgan Stanley assumed coverage of Ascendis Pharma (ASND) with an Overweight rating and $250 price target The firm is positive on the promising commercial trajectory of Yorvipath in hypoparathyroidism and the compelling opportunities presented by the TransCon pipeline, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
- Ascendis Pharma’s Competitive Edge in Achondroplasia Treatment: Buy Rating Supported by TransCon CNP’s Potential and Yorvipath Launch
- Ascendis Pharma price target raised to $224 from $215 at Oppenheimer
- Ascendis Pharma Grants Employee Warrants to Boost Retention
- Ascendis Pharma’s TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating